Lipid raft-associated cholesterol (LRAC)

Lipid raft-associated cholesterol refers to the concentrated pools of cholesterol found within specialized microdomains of the plasma membrane known as lipid rafts. These rafts serve as organizing centers for assembly of signaling molecules, influencing membrane fluidity and membrane protein trafficking. In estrogen receptor (ER)-negative breast cancer, these cholesterol-rich domains are often upregulated and play a critical role in maintaining the activity of pro-survival and migratory signaling pathways, such as the PI3K/Akt and Ras/MAPK pathways. By providing a platform for these oncogenic proteins, lipid raft cholesterol facilitates cancer cell proliferation, epithelial-to-mesenchymal transition (EMT), and metastasis. Therapeutic strategies targeting lipid raft-associated cholesterol involve the use of cholesterol-depleting agents or inhibitors of cholesterol biosynthesis. Drugs like methyl-beta-cyclodextrin (MβCD) can physically extract cholesterol from the membrane, while statins inhibit the HMG-CoA reductase enzyme to reduce the available pool of cholesterol for raft formation. Disruption of these domains leads to the dissociation of signaling complexes, effectively inhibiting the growth and invasive potential of aggressive ER-negative breast cancer cells. Research indicates that ER-negative cells may be more sensitive to these interventions compared to ER-positive cells, making lipid raft cholesterol a promising target for precision oncology in difficult-to-treat breast cancer subtypes.

Other names

Membrane cholesterolLipid raft cholesterolRaft-associated cholesterol

Depletion of membrane cholesterol or disruption of lipid raft integrity to inhibit oncogenic signaling pathways (e.g., Akt, MAPK) and induce apoptosis.